Amsterdam-based Tebi Announces €30 Million Investment Led by Alphabet growth fund CapitalG to transform hospitality operations
10.6.2025 16:05:00 EEST | Business Wire | Press release
Tebi, the Amsterdam-based startup developing an all-in-one financial operating system for hospitality, today announced a €30 million investment led by Alphabet independent growth fund CapitalG, with participation from existing investor Index Ventures. This follows Tebi’s €20 million Series A announced just six months ago and brings the company’s total funding to €56 million.
The financing reflects the company’s momentum across product innovation, hiring and expansion into new markets. The investment will support Tebi’s continued growth in these key areas of focus.
The company was founded in 2021 by technical alumni from Adyen, a €45B Dutch company, including serial entrepreneur Arnout Schuijff as CEO and Rob Vonk as CTO. Tebi is the third company co-founded by Schuijff, who previously served as Adyen’s longtime CTO and co-founder.
Aki Tas, former head of business strategy and operations at Notion, joined last fall as COO to lead the product, marketing, and foundation teams, and Patrick Studener, former COO at Wolt (now part of Doordash) and previous head of European expansion at Uber, joined at the beginning of the year as CCO to lead operational teams.
The investment will fuel Tebi's mission to transform operations for hospitality businesses worldwide. Until now, businesses have had to cobble together difficult-to-use solutions that lack key features, handle back-office tasks slowly and manually, and make it difficult to assess business performance. Tebi is rethinking hospitality technology from the ground-up, unifying the point of sale, payments, inventory management, a kitchen display system, reservations, and QR ordering functionality through an intuitive, mobile-first platform built on an accounting backbone. By being built around the point of sale, Tebi can coordinate both operations and finances for complex hospitality businesses. AI-enabled onboarding enables businesses to get started quickly, while the comprehensive platform simplifies and unifies workflows and makes key business metrics easily viewable.
Merchants across the Netherlands are already processing nine figures of payments annually on the platform. With this new investment, Tebi plans to accelerate product development, expand its reach globally, and grow its team. Beginning today, Tebi will also begin serving the UK market, marking the beginning of a broader global expansion strategy (UK customers can find Tebi at tebi.com/gb/).
"Hospitality businesses are the lifeblood of our communities, yet they've been underserved by technology, especially here in Europe," said Arnout Schuijff, co-founder and CEO of Tebi. "No one opens a restaurant or store because they love paperwork and integrating tools; they do it for the passion of serving people. It’s a privilege to build a world-class team devoted to empowering European business owners to free up time to focus on the craft and customers they cherish.”
“We are thrilled to partner with Tebi as they build the operating system for hospitality businesses,” said Alex Nichols, Partner at CapitalG. “Even though most small business front and back office workflows revolve around payments, three-quarters of Europe’s SMB payments are disconnected from software. By unifying these disjointed systems, Tebi is bringing greater efficiency and visibility to small business owners’ daily work. Arnout and his team combine focused customer centricity, speed, and unique founder-market fit. We couldn’t imagine a better team to pursue this massive opportunity.”
"Moving from disconnected systems – our previous POS software, a separate reservations platform, paper kitchen tickets, and a standalone payments provider – to Tebi's single integrated platform led us to embrace a new mindset at Zoldering. We approached it as if we were starting fresh, letting go of old habits to realize a seamless workflow from reservation to service to kitchen. Tebi has not just replaced our old systems; it has enabled a new way of working by unifying our data, streamlining communication between front and back of house, and offering the flexibility to adapt workflows to our specific needs – exactly what's required to maintain the standards expected of a Michelin-starred restaurant,” said Tomas and Job from Zoldering.
Tebi currently employs 35 people and is planning to double its headcount by the end of the year with roles open in Amsterdam and London.
About Tebi
Tebi is an all-in-one financial operating system for independent hospitality businesses. Founded in 2021, Tebi provides a comprehensive, mobile-first solution that includes point of sale, integrated payments, a kitchen display system, reservations, inventory management, QR ordering, and bookkeeping. With its unique pricing model and commitment to merchant success, Tebi is dedicated to empowering hospitality businesses everywhere. To learn more about adopting Tebi for your business, visit www.tebi.com.
Tebi is currently hiring across all functions, including engineering, product management and operations in both Amsterdam and London. Visit Tebi’s careers page to see all open positions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610225196/en/
Contacts
Melissa Sobel, melissasobel@capitalg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom